Abstract
Objectives To investigate the alleged relationship between leaders’ gender and COVID-19 related cases and deaths in different countries across the globe.
Study design The relationship between leaders’ gender and percent of women in parliament to COVID-19 cases and death per million was investigated in three time points (10 months) across 180 countries, controlling for possible covariates.
Methods Three different types of analyses were run: (1) Six basic t-tests; (2) Two repeated-measure ANOVA tests analyzing change over time; (3) Six stepwise regression analyses for both leaders’ gender and the percentage of women in parliament.
Results Our findings suggest that, contrary to some research and popular media headlines, and in-line with recent academic research, leadership gender is not a significant factor in explaining the variation between countries in the fight against the COVID-19 pandemic.
Conclusions We suggest that this alleged relationship may stem from an illusory correlation. We argue that the uncertainty, stress, and anxiety that prevail in these times of global pandemic may be the breeding ground for judgmental biases of this sort.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used in this analysis were retrieved from Windsor LC, Yannitell Reinhardt G, Windsor AJ, Ostergard R, Allen S, Burns C, Giger J, Wood R. Gender in the time of COVID-19: Evaluating national leadership and COVID-19 fatalities. PloS one. 2020 Dec 31;15(12):e0244531. and Our World in Data
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The revised manuscript is identical to the original one only that it now includes the link for the "Supplementary Materials" (the original manuscript said: "An OSF link that will be added upon acceptance").
Data Availability
Data availability statement: The data that support the findings of this study are openly available at https://osf.io/g3n4v/?view_only=915933f0c4e745fca3bf66549d6fa23c
https://osf.io/g3n4v/?view_only=915933f0c4e745fca3bf66549d6fa23c
